Notable Biopharma Fundraises in August: Powering Promising Treatments

In August 2024, several notable biopharma companies announced substantial funding rounds. These funds are poised to drive the development of promising treatments across various indications and modalities.

Here, we delve into the details of some of the most significant fundraises, highlighting the companies, their innovative approaches, and the potential impact on patient care.

Outpace Bio: Enhancing CAR-T Cell Therapy for Solid Tumors

Outpace Bio, a Seattle-based cell therapy company, raised $144 million in a Series B financing round led by RA Capital Management. The company is leveraging AI-powered protein design to enhance immune cells performance in patients battling solid tumors.

Their lead therapy, OPB-101, is a mesothelin-specific chimeric antigen receptor (CAR) T cell designed to work better against solid tumors like ovarian and other cancers. Existing cell therapies have worked well against blood cancers, but shown limited responses in treating solid tumors.

In its August 2024 financing announcement, Outpace Bio expected FDA clearance for its investigational new drug (IND) application and first dosing of OPB-101 in 2025, in patients with advanced platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Update: the trial’s ClinicalTrials.gov record, last updated December 18, 2025, lists an actual study start date of June 16, 2025. Source

Borealis Biosciences: Harnessing xRNA for Kidney Diseases

Borealis Biosciences, an independent, discovery-stage biotechnology company based in Vancouver, announced $150 million in combined Series A financing and committed research collaboration funding to develop next-generation xRNA-based medicines for kidney diseases. Novartis and Versant Ventures launched Borealis Biosciences around members of Chinook's Vancouver research team, combining a Series A investment with a research collaboration. As part of the agreement, Novartis committed up to $100 million in upfront and near-term research funding combined. Novartis also has the option to acquire two future development-ready programs from Borealis, with up to $750 million in total consideration, including clinical and regulatory milestones. Source

Borealis is developing RNA medicines for kidney diseases. Borealis capitalizes on the success of Chinook Therapeutics, a kidney disease company founded by Versant in 2019 and acquired by Novartis for up to $3.5 billion in 2023. The Borealis team includes researchers from Chinook, among additional leaders from the RNA therapeutics field. Source

Halda Therapeutics: Precision Targeting with RIPTAC Technology

Halda Therapeutics secured $126 million in a Series B extension to fund clinical trials of their first-in-class RIPTAC (Regulated Induced Proximity Targeting Chimeras) drug candidates for major solid tumors, such as breast cancer and prostate cancer. RIPTAC therapeutics are designed to address cancer's ability to develop resistance mechanisms, which is a common limitation of current precision oncology medicines.
Source

RIPTACs are bifunctional small molecules designed to kill cancer cells selectively through a "hold and kill" mechanism. They form a ternary complex comprising the drug, a protein enriched in tumor cells, and a protein essential for cell survival. Disrupting the essential protein’s function is intended to cause cancer-cell death. At the time of the financing, this approach was supported by preclinical research; selective activity did not establish safety or efficacy in patients.
Source

In August 2024, Halda Therapeutics planned to initiate its Phase 1 trial in metastatic, castration-resistant prostate cancer (mCRPC) in the first half of 2025. Update: its ASCO 2025 trial-in-progress poster reported that the first patient received HLD-0915 in February 2025. Source

IDRx: Targeting KIT Mutations in GIST

IDRx Inc. raised $120 million in a Series B round to support the ongoing Phase 1/1b StrateGIST 1 study of its lead product candidate IDRX-42, a potent, oral, highly selective KIT inhibitor for KIT-mutant gastrointestinal stromal tumors (GIST). [Source]

At the 2024 American Society of Clinical Oncology (ASCO) annual conference, IDRx presented preliminary Phase 1 data from the StrateGIST 1 trial. IDRx described the findings as supporting the best-in-class potential of IDRX-42 in patients with GIST; these early data did not establish superiority over other treatments. By August 2024, the FDA had granted Fast Track designation for GIST after progression on or intolerance to imatinib, and Orphan Drug designation for GIST.
Source

These significant fundraises highlight the continued momentum in the biopharma industry, with companies continuing to leverage cutting-edge technologies and innovative approaches to tackle various indications, including solid tumors, kidney diseases, and rare cancers. As these companies advance their programs through clinical development, their efforts hold the potential to bring transformative treatments to address unmet needs.